FETA (Phase 2) is a research study of how Neisseria gonorrhoeae regulates FetA, a receptor that enables the bacterium to take up iron bound to ferric enterobactin, a siderophore. The study was conducted by researchers at the University of North Carolina at Chapel Hill, in Chapel Hill, United States, and published in Molecular Microbiology in May 2000. The authors were Susan D. Carson, Barbara Stone, M. Beucher, J. Fu and P. Frederick Sparling.1
The team examined FetA expression in gonococcal strain FA1090, focusing on shifts between high- and low-expression states. They reported that switching occurred in both directions at an estimated frequency of about 1.3%. Expression levels tracked the length of a run of cytosine bases near the fetA transcription start site, between the putative −10 and −35 promoter sequences.1
The authors proposed that this rapid variation may reflect competing pressures: expressing FetA can help the bacterium obtain iron, while reducing its expression may help it avoid recognition by the host immune system. Their rationale included the observation that infected patients commonly produce antibodies against FetA; the proposed balance is an interpretation, rather than a demonstrated clinical outcome.1
The work’s scope was a laboratory investigation of gene-expression variation and its possible biological significance. The PubMed record identifies U.S. Public Health Service support and lists NIH/NIAID grants R37 AI26837, T32 AI07001 and U19 AI31496.1